Hive Prospect · Evidence before recommendation
Drug asset scouting, with evidence before recommendation.
You give Hive a search brief: the science you want, what you can spend, where a study could run, and what you need to learn. Hive keeps incomplete leads in research and releases only assets that meet every required test.
You put in
“Find drugs that fit this scientific goal, have readable human data, may be available to license, and can answer this question within my trial budget.”
Your licensing budget, trial budget, timing, countries and exclusions are separate inputs.
You get back
A dated shortlist when evidence supports one. For each qualifying asset: the owner, why work stopped, evidence for and against it, a costed next step and the reason it fits your brief.
No passing assets means an honest empty shortlist, with progress counts and the decisions still needed.
Two gates. No shortcuts.
- First, establish identity, current status, stopping reason, ownership and availability.
- Then test scientific fit, readable human data, stopping reason, reachable rights, affordability and a measurable early endpoint.
- Only passing assets can be ranked. New evidence or an expired verification can remove a previous pass.
The qualification workflow is available. Live source coverage and individual rights checks remain work to verify. The focused investigation is $2,500 after scope and start date are agreed; this form does not charge you. See the scope · Read an example report.